Cat. No. 1490
Alternative Names: 4-Methoxy-7-nitroindolinyl-caged-L-glutamate, MNI glutamate
Chemical Name: (S)-α-Amino-2,3-dihydro-4-methoxy-7-nitro-δ-oxo-1H-indole-1-pentanoic acid
Biological ActivityMNI-caged glutamate that rapidly and efficiently releases glutamate (Cat.No. 0218) when photolysed (300 - 380 nm excitation). Water-soluble, highly resistant to hydrolysis, stable at neutral pH, and pharmacologically inactive at neuronal glutamate receptors (up to mM concentrations). 2.5-fold more efficient at releasing L-glutamate than NI-caged L-glutamate.
Licensing InformationSold under license from the Medical Research Council
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Papageorgiou and Corrie (2000) Effects of aromatic substitutions on the photocleavage of 1-acyl-7-nitroindolines. Tetrahedron 56 8197.
Canepari et al (2001) Photochemical and pharmacological evaluation of 7-nitroindolinyl- and 4-methoxy-7-nitroindolinyl-amino acids as novel, fast caged neurotransmitters. J.Neurosci.Methods 112 29. PMID: 11640955.
Matsuzaki et al (2001) Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat.Neurosci. 4 1086. PMID: 11687814.
Maier et al (2005) Comparative analysis of inhibitory effects of caged ligands for the NMDA receptor. J.Neurosci.Methods 142 1. PMID: 15652611.
Palma-Cerda et al (2012) New caged neurotransmitter analogs selective for glutamate receptor sub-types based on methoxynitroindoline and nitrophenylethoxycarbonyl caging groups. Neuropharmacology. 63 624. PMID: 22609535.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MNI-caged-L-glutamate, supplier, Stable, photoreleaser, L-glutamate, Caged, Compounds, Glutamate, mGlur, Receptors, Metabotropic, Non-Selective, iGlur, Ionotropic, agonists, MNI, glutamate, MNI-Glutamate
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.